The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients.
It was the aim of this study to test for a possible effect of the new non ergot dopamine agonist CV 205-502 on plasma growth hormone (GH) concentrations in acromegaly. 10 acromegalic patients received a single oral dose of 150 micrograms CV 205-502 after an overnight fast. As a control group 7 acromegalic patients undertook the same procedure without receiving any drug. Blood samples were drawn hourly up to 7 hours thereafter for determination of GH. Plasma growth hormone concentrations decreased by 48.8 +/- 8.7%. The nadir was observed 3 hours after CV 205-502 was administered and GH concentrations remained suppressed throughout the 7 hours of the test period. In contrast GH plasma concentrations in the control group remained stable. We conclude that acute administration of CV 205-502 suppresses GH secretion in acromegalic patients and thus could serve as an alternative therapy in acromegaly.
Svoboda
T
T
Department of Medicine III, University of Vienna, Austria.
Kotzmann
H
H
Clodi
M
M
Bernecker
P
P
Geyer
G
G
Luger
A
A
D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D000634:Aminoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged
D000634:Aminoquinolines; D015259:Dopamine Agents; C046650:quinagolide; D013006:Growth Hormone